Phase 3Active, not recruiting

A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Efficacy and Safety Study of Subcutaneous Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)

Sponsor
Swedish Orphan Biovitrum (Industry)
Enrollment
15 enrolled
Conditions
Still's Disease, Juvenile Onset; Still's Disease, Adult-Onset
Interventions
Anakinra; Placebo
Ages
children, adults, older adults
Registry
NCT05814159

Full record on ClinicalTrials.gov

From the registry

A study to demonstrate efficacy and safety of anakinra in pediatric and adult Japanese patients with Still's disease (Systemic juvenile idiopathic arthritis \[SJIA\] and Adult-onset Still's disease \[AOSD\]).

Primary outcomes

  • An improvement of ≥ 30% from baseline in physician global assessment of disease activity (visual analogue scale [VAS]).
  • An improvement of ≥ 30% from baseline in patient/parent global assessment of overall well-being (VAS).
  • An improvement of ≥ 30% from baseline in number of joints with active arthritis.
  • An improvement of ≥ 30% from baseline in number of joints with limitation of motion.

History

  1. Study completion

  2. Primary completion

  3. Last registry update

  4. Registered

  5. Started